[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cigarette-smoking-related-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cigarette-smoking-related-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,40,65,88,109,130,151,169,188,207,226,249,269,289,309,329,349,368],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100439942","phase-3-reaching-rural-cancer-survivors-who-smoke-using-text-based-program-100439942",false,"NCT05008848","Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program","Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions","Inclusion Criteria:\n\n* Have a cancer diagnosis within the past 10 years, and can currently be receiving curative treatment\n* Not currently on hospice\n* Currently smokes \\>= 5 cigarettes daily\n* Lives in a nonmetro\u002Frural county (defined as having a Rural Urban Continuum Code \\[RUCC\\] code of 4-9)\n* Patient interested in participating in a smoking cessation program, and not currently participating in a smoking cessation clinical trial\n* Not currently using any smoking cessation pharmacotherapy (e.g. nicotine replacement therapy, bupropion or varenicline), or currently participating in any cessation program\n* Patient has a cell phone or smart phone device with texting ability\n* In order to complete the mandatory patient-completed measures, participants must be able to speak and read English\n* Age \\>= 18 years\n* Participant must be willing to provide a urine sample.\n\nExclusion Criteria:\n\n* Psychiatric illness which would prevent the patient from giving informed consent\n* Patients with impaired decision-making capacity are not eligible for this study.","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.",[26],"Cigarette Smoking-Related Carcinoma","RECRUITING","2026-07-01",{"date":30,"type":31},"2026-07-02","ACTUAL",{"date":33,"type":31},"2022-04-01",{"date":35,"type":20},"2027-08-01",{"name":37,"class":38},"Alliance for Clinical Trials in Oncology","OTHER",222,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100520335","phase-1-pkpd-of-vaping-thc-containing-liquids-vs-smoked-cannabis-100520335","NCT06055231","PK\u002FPD of Vaping THC-containing Liquids vs. Smoked Cannabis","A Randomized Within-Subject Cross-Over Study to Compare Short-Term PK\u002FPD Effects of Vaping THC-containing Liquids vs. Smoked Cannabis","Inclusion Criteria:\n\n* Age \\>= 21 years of age\n* Report concurrent use of commercial (medical or recreational) smoked cannabis and THC vaping cartridges for at least 3 months prior to enrollment\n* Report smoking cannabis and THC- vaping liquid use at the potency level of the study product at least weekly (4x\u002Fmonth)\n* Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products\u002Fprocedures\n* Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#:NCE-STHC-1) and semi -quantitative urinary tetrahydrocannabinol-carboxylic acid (THCA) rapid test (NarcoCheck® THC PreDosage) during baseline testing, prior to receiving any study-related products\n* Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* • Illegal or non-prescription drug use within the past 90 days. As detected by NacroCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product\n\n  * Report 2 or more drinking occasions\u002Fweek with 4 or more drinks\u002Foccasion\n  * Report of daily nicotine use\n  * Current or prior diagnosis of any psychotic disorders\n  * Current or prior diagnosis of chronic heart conditions\n  * Current or prior diagnosis of any respiratory condition\n  * Pregnant or currently trying to become pregnant (females)\n  * Detection level 4-5 (\\>300 ng\u002FmL) from a semi-quantitative urinary THCA rapid test (NarcoCheck® THC PreDosage)\n  * Unwilling or unable to follow protocol requirements\n  * Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation",true,"21 Years",{"count":50,"type":20},40,[52],"PHASE1","We will conduct a randomized, within-subjects clinical study to compare short-term pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ9-tetrahydrocannabinol (THC) vaping liquids vs. smoked cannabis containing 6 equivalent standard THC units (5 mg THC=1 Standard THC Unit (STU)) in healthy community members who are current users of both products. While smoking cannabis remains the most common mode of THC use among adults and youth, alternative modes of delivery, such as Electronic Vaping Products (EVPs), are becoming increasingly popular for the delivery of cannabinoids. Declining cannabis risk perceptions, increasing normalization of cannabis, greater legal access and availability to cannabis, ease of administration, and ability to conceal vaped THC use have likely contributed to increasing prevalence of use throughout the population across all age groups. Comparing vaping THC containing liquids with smoking cannabis can serve as an important benchmark for evaluating the delivery and effects of THC vaping products and, their relative safety",[26],"NOT_YET_RECRUITING","2026-06-29",{"date":58,"type":31},"2026-06-30",{"date":60,"type":20},"2026-08-01",{"date":62,"type":20},"2027-09-15",{"name":64,"class":38},"Roswell Park Cancer Institute",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100574765","oral-nicotine-pouches-versus-nicotine-replacement-therapy-to-reduce-cigarette-use-for-smokers-in-rural-appalachia-100574765","NCT06763536","Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia","Testing Oral Nicotine Pouches to Reduce Smoking-Related Cancer in Rural Appalachia","ARISE","Inclusion Criteria:\n\n* Read and speak English\n* 21 years or older\n* Smoke ≥ 5 cigarettes per day for the past year\n* Willing to use Oral Nicotine Pouches (ONP) or Nicotine Replacement Therapy (NRT)\n* Live in a rural Appalachian County\n* Have a smartphone and\u002For willing to use a smartphone for study purposes (smartphones may be provided to participants for study purposes only)\n* Willing to blow air into a handheld study device\n* If capable of becoming pregnant, verbal confirmation of not being pregnant based on urine pregnancy test results\n\nExclusion Criteria:\n\n* Report currently using smoking cessation medications, NRT, or actively seeking treatment for smoking cessation\n* Use of ONPs in past 3 months\n* Use of Nicotine Replacement Therapies in past 3 months\n* Use of other tobacco products \\> 10 days\u002Fmonth\n* Unstable or significant medical condition\n* Unstable or significant psychiatric conditions (past and stable conditions will be allowed)\n* History of cardiac event or distress within the past 3 months\n* Live in same household as another study participant.\n* Currently pregnant, planning to become pregnant within 6 months, or breastfeeding",{"count":74,"type":20},1000,[76],"NA","This clinical trial compares the use of oral nicotine pouches to nicotine replacement therapy, consisting of nicotine patches and lozenges, to reduce cigarette use in smokers living in rural Appalachia. The lung and oral cancers that plague Appalachia are fueled by cigarette smoking. Oral nicotine pouches which contain nicotine but no tobacco leaf, present a new opportunity to reduce cancer risk among Appalachian adults who smoke. Oral nicotine pouches and nicotine replacement therapy may work well to reduce cigarette use for smokers in rural Appalachia.",[26],"2026-06-26",{"date":58,"type":31},{"date":82,"type":31},"2025-06-13",{"date":84,"type":20},"2028-12-31",{"name":86,"class":38},"Ohio State University Comprehensive Cancer Center",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":87},"100627967","a-novel-tobacco-cessation-resource-for-smokers-with-a-diagnosed-or-suspected-thoracic-cancer-100627967","NCT07455513","A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer","A Pilot\u002FFeasibility Study of the Buckeye Quit Stick: A Novel Resource for Successful Tobacco Cessation","Inclusion Criteria:\n\n* \\>= 21 years old\n* Speak and understand English\n* Established patient of the OSU thoracic clinics\n* Diagnosed with a thoracic malignancy or has a clinically suspected thoracic malignancy as documented by treating provider\n* Willing and able to participate in the study protocol (e.g., complete the survey and related study documents and provide informed consent)\n* Current self-reported smoker\n* Willingness to change = score of above 1 on the Stages of Change measure\n\nExclusion Criteria:\n\n* \\\u003C 21 years old (Ohio is a tobacco 21 state.)\n* Patient outside of the OSU clinics (This intervention targets patients who may benefit the most from cessation.)\n* Unwilling or unable to provide consent or complete study components\n* Prisoners will be excluded from participation",{"count":96,"type":20},30,[76],"This clinical trial evaluates the feasibility of a novel tobacco cessation resource called a Buckeye Quit Stick among smokers with a diagnosed or suspected thoracic cancer. Tobacco use is the single most preventable cause of disease, disability, and death in the United States. While the benefits of quitting smoking are numerous, rates of persistent smoking after cancer diagnosis remain high. Research has found that patients who quit smoking but subsequently relapse frequently report the hand\u002Foral habit as a barrier to sustained smoking cessation. The Buckeye Quit Stick is an innovative cessation aid designed to directly address patients' hand\u002Foral habit by substituting the cessation aid for cigarettes without integrating pharmacologic intervention, which is typically managed by their medical provider and may require direct supervision due to the patient's health status. The Buckeye Quit Stick is designed to satisfy the repeated hand\u002Foral pattern or ritual, thereby avoiding the physical loss of holding a cigarette in the hand or mouth and the action of smoking. It may also help occupy fidgeting hands and potentially reduce stress and cravings. This novel cessation resource may address key factors that influence smoking abstinence and improve patients' health outcomes.",[26,100],"Malignant Thoracic Neoplasm","2026-06-12",{"date":103,"type":31},"2026-06-15",{"date":105,"type":31},"2026-02-25",{"date":107,"type":20},"2027-03-31",{"name":86,"class":38},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":87},"100532494","connecting-to-lungcare-100532494","NCT06213532","CONNECTing to LungCare","Inclusion Criteria:\n\n* English, Spanish and Cantonese speaking\n* Age \\>= 18 years old\n* Primary care patients at the University of California, San Francisco (UCSF) General Internal Medicine (GIM) clinics\n* Must be current smokers and\u002For candidates for Lung Cancer Screening (LCS).\n\nKey Informant Interviews:\n\n\\- Must be working in one of the clinics participating in CONNECTing to LungCare.\n\nExclusion Criteria:\n\n* Not a current smoker",{"count":116,"type":20},152,[76],"This study evaluates a smoking cessation intervention (CONNECTing to LungCare) for improving shared decision-making conversations about smoking cessation and lung cancer screening between patients and providers. Shared decision making is a patient care model in which providers offer information regarding risks and benefits, patients express their values and preferences, and then healthcare decisions are jointly discussed between the patient and provider. Patient education, aided by decision support tools, can increase patients' knowledge, decrease their decisional conflict, promote decision making, and improve the patients' perception of risk. CONNECTing to LungCare is an interactive education intervention that addresses lung cancer screening and smoking cessation and provides participants with a tailored summary that may make them more likely to have shared decision-making discussions with their providers about smoking cessation and lung cancer screening.",[120,26,121],"Smoking Cessation","Lung Carcinoma","2026-06-11",{"date":103,"type":31},{"date":125,"type":31},"2024-12-03",{"date":127,"type":20},"2026-11-30",{"name":129,"class":38},"University of California, San Francisco",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":87},"100578418","phase-3-icanquit-smoking-cessation-among-hispanic-adults-100578418","NCT06811038","iCanQuit Smoking Cessation Among Hispanic Adults","Providing Nicotine Replacement Therapy to Enhance the Efficacy of a Smoking Cessation Smartphone App for Hispanic Adults","Inclusion Criteria:\n\n* Self-identify as Hispanic ethnicity\n* Age 18 and older\n* Smoking at least one cigarette per day in the past 30 days\n* Want to quit smoking within 30 days\n* Interest in learning skills to quit smoking\n* Willing to be randomly assigned\n* United States (US) or Puerto Rico (PR) residency for the next twelve months\n* Have daily access to their own Android or iPhone smartphone\n* Ability to download a smartphone application (app)\n* Proficiency in English or Spanish\n* Not currently (i.e., within past 30 days) using other smoking cessation interventions\n* Willing to consider using NRT\n* No previous use of iCanQuit\n* No household or family member participating\n* Willingness to complete follow-up assessments at the 3-, 6-, and 12-month follow-ups\n* Providing email, phone number(s), and mailing address\n\nExclusion Criteria:\n\n* NRT CONTRAINDICATION: Heart attack in the last 2 months\n* NRT CONTRAINDICATION: Stroke in the last 6 months\n* NRT CONTRAINDICATION: Diagnosed arrhythmia or tachycardia\n* NRT CONTRAINDICATION: Uncontrolled hypertension\n* NRT CONTRAINDICATION: Currently using warfarin\n* NRT CONTRAINDICATION: Pregnant or breastfeeding, or plans to become pregnant during the next 6 months",{"count":138,"type":20},854,[23],"This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with personalized quit plans. Nicotine replacement therapy works by giving small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking without any of the other harmful chemicals found in tobacco products.",[26],"2026-06-08",{"date":144,"type":31},"2026-06-09",{"date":146,"type":20},"2026-08-15",{"date":148,"type":20},"2030-07-01",{"name":150,"class":38},"Fred Hutchinson Cancer Center",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":87},"100569688","a-smartphone-application-quitbot-for-the-improvement-of-smoking-cessation-among-american-indians-and-alaska-natives-naitive-trial-100569688","NCT06697496","A Smartphone Application (QuitBot) for the Improvement of Smoking Cessation Among American Indians and Alaska Natives, NAITIVE Trial","Navigation and Artificial Intelligence Technology for Indigenous Virtual Education on Smoking Cessation (NAITIVE)","Inclusion Criteria:\n\n* Self-identifying as American Indian or Alaska Native, either alone or in combination with other races\n* Age 18 and older\n* Smoking combustible cigarettes daily in the past year\n* Interest in quitting smoking\n* Interest in learning skills to quit smoking\n* Willing to be randomly assigned\n* Have daily access to their own Android or iPhone smartphone\n* Ability to download a smartphone app\n* Ability to read English\n* Not currently (i.e., within past 30 days) using other smoking cessation interventions\n* No prior participation in our studies\n* No prior use of SFT\n* No household or family member participating\n* US residency for the next twelve months\n* Willingness to complete follow-up assessments at the 3-, 6-, and 12-month follow-ups\n* Providing email, phone number(s), and mailing address\n\nExclusion Criteria:\n\n* The reverse of the inclusion criteria\n* Pregnant or breastfeeding\n* Use of other tobacco products (e.g., ceremonial use of tobacco, e-cigarettes) will be assessed but is not an exclusion criterion, as it would limit the study's generalizability",{"count":159,"type":20},772,[76],"This clinical trial develops a chatbot smartphone application (app), QuitBot, and text messaging to help American Indians (AI) and Alaska Natives (AN) to quit smoking commercial tobacco (smoking cessation), and evaluates two remote smoking cessation programs to see how well they work for helping AI\u002FAN people quit smoking commercial tobacco. AI\u002FAN populations have one of the highest rates of commercial cigarette smoking of any racial and ethnic group in the United States (US). They also have a higher rate of developing smoking-related cancer but are less likely to quit smoking. The two programs are designed to provide personalized support in setting a smoking cessation goal, tasks to reach the smoking cessation goal, and motivation to remain smoke-free. This may help to keep participants engaged and support them in their quit efforts, and may improve smoking cessation among AI and AN.",[26],{"date":144,"type":31},{"date":165,"type":20},"2026-09-30",{"date":167,"type":20},"2030-10-31",{"name":150,"class":38},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":87},"100630867","a-behavioral-application-for-improving-smoking-cessation-among-smokers-100630867","NCT07493252","A Behavioral Application for Improving Smoking Cessation Among Smokers","Actify! An mHealth Mood Management Tool to Improve Population-Level Smoking Cessation","Inclusion Criteria:\n\n* Age 18 or older\n* Currently smoke, averaging at least 5 cigarettes\u002Fday for the last 30 days\n* Interested in quitting smoking in the next 30 days\n* Experience downloading and using one or more apps on their smartphone\n* Either screens negative for depression (Patient Health Questionnaire - 9 item \\[PHQ-9\\] score 0-4; n = 906) or screens positive for mild to moderately severe current depressive symptoms (PHQ-9 score 5-19; n = 906)\n* Willing and able to complete all study activities and to receive compensation by mail\n* Comfortable reading and writing in English\n* Have a mobile data plan and\u002For access to WiFi to support the use of the assigned app\n* Reside in the United States (US)\n* Willing to provide information for an emergency contact in case of serious concerns about the participant's physical or mental health\n\nExclusion Criteria:\n\n* Self-report of currently receiving behavioral treatment for depression (e.g., psychotherapy or counseling, web- or app-based interventions); current use of pharmacotherapy for depression or for other mental health conditions that are not otherwise excluded is allowable (e.g., benzodiazepines, anticonvulsants, opioid agonists, antipsychotics)\n* Severe depression (PHQ-9 ≥ 20)\n* Current suicidal ideation reported on the PHQ-9\n* History of a suicide attempt\n* Self-reported lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, antisocial personality disorder, or borderline personality disorder; or self-reported lifetime diagnosis of an alcohol or drug use disorder with use of the substance(s) in the past 30 days\n* Currently receiving other smoking cessation treatments, including pharmacotherapies (nicotine replacement therapy, bupropion, or varenicline) and behavioral interventions (e.g. quitline counseling, other digital health programs), but excluding electronic (e)-cigarettes\u002Fvaping\n* Previous use of the QuitGuide program\n* Employees\u002Ffamily of investigator or study center\n* Member of the same household as another participant\n* Woman who is pregnant or breastfeeding, or planning to become pregnant\n* Having a Google voice number as their primary phone number (due to association with fraudulent study entry attempts in our previous work)\n* Currently incarcerated\n* Participated in earlier studies to develop the Actify! app",{"count":177,"type":20},1812,[76],"This clinical trial compares two smartphone applications, called Actify! (A \\& B) for improving smoking cessation outcomes in individuals who smoke. Actify! A is an app grounded in behavioral activation therapy, an evidence-based treatment for depression that can also be used to modify health behaviors such as smoking. The Actify! B app provides evidence-based tobacco cessation strategies based on current clinical guidelines.",[26],"2026-06-01",{"date":183,"type":31},"2026-06-03",{"date":60,"type":20},{"date":186,"type":20},"2029-07-31",{"name":150,"class":38},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":87},"100626733","understanding-tobacco-and-cannabis-co-use-practices-initiation-escalation-and-maintenance-100626733","NCT07439471","Understanding Tobacco and Cannabis Co-Use Practices: Initiation, Escalation, and Maintenance","Inclusion Criteria:\n\n* \\* Adults aged 18 to 30 years old.\n\n  * Currently living in the Roswell Park catchment area.\n  * Able to speak, read, and write in English.\n  * Currently consuming cannabis at least weekly.\n\n    * Group 1: currently using cigarettes daily and not using nicotine vaping products more than one day per week.\n    * Group 2: currently using nicotine vaping products daily and not using cigarettes more than one day per week.\n\nExclusion Criteria:\n\n* \\* Unwilling or unable to follow protocol requirements.\n\n  * Individuals under the age of 18 or over 30.\n  * Individuals not meeting product consumption criteria for inclusion items 3 and 4.","30 Years",{"count":50,"type":20},"OBSERVATIONAL","This study evaluates histories among cannabis and tobacco co-users of their initiation, escalation, and maintenance of the co-use behavior.",[26],"2026-05-21",{"date":201,"type":31},"2026-05-22",{"date":203,"type":20},"2026-06-28",{"date":205,"type":20},"2027-03",{"name":64,"class":38},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":87},"100638917","evaluating-the-effect-of-nicotine-on-eye-movements-and-related-behaviors-in-electronic-cigarette-users-nics-eyes-trial-100638917","NCT07604246","Evaluating the Effect of Nicotine on Eye Movements and Related Behaviors in Electronic Cigarette Users, NICS-EYES Trial","Nicotine Effects on Eye Movements and Self-Report Measures (NICS-EYES)","Inclusion Criteria:\n\n* Age 21-50 years\n* Daily use of nicotine-containing electronic cigarettes for ≥ 6 months\n* Ability to abstain from nicotine for at least 12 hours prior to study visits\n* Fluent in English\n* Willingness to complete two in-person laboratory visits and all study procedures\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Use of combustible cigarettes or other tobacco\u002Fnicotine products on more than 5 of the past 30 days\n* Current enrollment in a nicotine cessation program or intent to quit in the next 30 days\n* Neurological conditions affecting eye movements (seizure disorder, movement disorders, head injury with loss of consciousness)\n* Normal or corrected-to-normal vision required; significant uncorrected visual impairment or ocular conditions affecting eye tracking\n* Cardiovascular conditions for which nicotine use is contraindicated, substance use disorder (other than nicotine), or current nicotine cessation treatment\n* Pregnancy or breastfeeding\n* Current medications affecting pupil size or eye movements (anticholinergics, stimulants, antipsychotics)\n* Any condition that, in the investigator's judgment, would interfere with safe participation\n* Age younger than 21 years or older than 50 years","50 Years",{"count":216,"type":20},25,[76],"This clinical trial evaluates the effect of nicotine on eye movements and related behaviors in people who use electronic (e)-cigarettes. Nicotine is an addictive, poisonous chemical found in tobacco. It can also be made in the laboratory. When it enters the body, nicotine causes an increased heart rate and the use of oxygen by the heart and a sense of well-being and relaxation. E-cigarettes are the most commonly used tobacco products in young adults in the United States. E-cigarettes deliver nicotine rapidly and the potential for addiction (abuse liability) is comparable to combustible cigarettes. The Food and Drug Administration uses a combination of testing including self-reported scales, withdrawal assessments and behavioral tasks to evaluate the abuse liability of a nicotine product. Research has shown that nicotine alters movement of the eye (oculomotor) and the amount of nicotine in the blood impacts the extent of oculomotor function impairment. Despite this evidence linking nicotine to oculomotor changes, it has not been studied as a reliable marker for abuse in e-cigarette users. Studying eye movements can provide information about how the brain responds to nicotine and may help researchers develop better, more objective ways to measure how addictive nicotine products in e-cigarette users.",[26],"2026-05-18",{"date":201,"type":31},{"date":60,"type":20},{"date":224,"type":20},"2027-12-31",{"name":86,"class":38},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":21,"phases":235,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":245,"locationsCount":248},"100448561","phase-2-testing-the-effect-of-the-broccoli-seed-and-sprout-extract-avmacol-es-on-the-cancer-causing-substances-of-tobacco-in-heavy-smokers-100448561","NCT05121051","Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers","Phase II Randomized, Double Blind, Placebo-Controlled Trial of Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers","Inclusion Criteria:\n\n* Male or female current tobacco smokers with \\>= 20 pack years of self-reported smoking exposure and a current average use of \\>= 10 cigarettes\u002Fday\n* Age \\>= 18 years. No upper age limit\n* Karnofsky performance scale \\>= 70%\n* Absolute neutrophil count \\>= 1,000\u002Fmicroliter\n* Platelets \\>= 100,000\u002Fmicroliter\n* Total bilirubin =\\\u003C 2 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 3 x ULN\n* Creatinine =\\\u003C 1.5 x ULN\n* Participants with known human immunodeficiency virus (HIV) infection are not eligible for this trial due to potential interaction between sulforaphane and anti-retroviral therapy\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment are not eligible due to potential interaction between sulforaphane and anti-retroviral therapy\n* The effects of BSSE on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of invasive cancer within the past 2 years, except for excised and cured non-melanoma skin cancer or carcinoma in situ of the cervix. Participants who continue adjuvant treatment for an index cancer occurring \\> 2 years ago, such as adjuvant hormonal therapy for breast cancer, are excluded. Participants who are on anti-neoplastic treatment for a chronic malignancy, such as multiple myeloma or chronic myelogenous leukemia, are excluded\n* Ongoing use of a nutraceutical or dietary supplement containing glucoraphanin or sulforaphane\n\n  * Note, participants will be eligible if they agree to stop the glucoraphanin or sulforaphane product at least 7 days prior to the baseline visit (7-day washout)\n* Participants with known chronic hepatitis B virus (HBV) infection are not eligible for this trial due to potential interaction between sulforaphane and suppressive anti-viral therapy\n* Participants may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Avmacol ES® (BSSE)\n* Uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia\n* Any other condition or lifestyle factor, that, in the opinion of the principal investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant\n* Pregnant or lactating women. Pregnant women are excluded from this study because the effects of BSSE on the developing human fetus are unknown. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with BSSE, Breastfeeding should be discontinued if the mother is treated with BSSE",{"count":234,"type":20},135,[236],"PHASE2","This phase II trial tests whether broccoli seed and sprout extract works to break down cancer causing substances of tobacco in heavy smokers. Smokers are at increased risk for developing lung, head and neck, and other cancers. Broccoli seed and sprout extract may help break down and remove toxic substances caused by tobacco use and possibly produce substances that may protect cells from tobacco smoke-induced damage in current smokers.",[26],"2026-05-12",{"date":241,"type":31},"2026-05-13",{"date":243,"type":31},"2022-09-21",{"date":224,"type":20},{"name":246,"class":247},"National Cancer Institute (NCI)","NIH",3,{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":196,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":87},"100605800","carcinogen-and-toxicant-exposure-among-young-adults-who-co-use-e-cigarettes-and-cannabis-co-tox-study-100605800","NCT07167225","Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)","Inclusion Criteria:\n\n* Young adult (18-25 years old).\n* Ability to read and write in English.\n* Participants must fall into one of the following groups (based on self-report):\n* Predominant e-cigarette consumer: defined as using nicotine-containing e-cigarettes daily for the past six months but not having used other nicotine containing products more than weekly or cannabis products for the past month.\n* Predominant cannabis consumer: defined as using cannabis at least 3x\u002Fweek for the past six months in any form, including smoking, vaping, and oral use, with no more than weekly use of any nicotine or tobacco products.\n* E-cigarette-cannabis co-consumers: defined as daily use of nicotine e-cigarettes and use of cannabis at least 3x\u002Fweek, including smoking, vaping, and oral use, for at least the past six months, with no use of other nicotine containing products more than weekly.\n* No self-reported diagnosis of kidney disease (current, or within the past year prior to the study visit).\n* Participants must understand the voluntary nature of this study and sign a written informed consent form before proceeding with study activities.\n\nExclusion Criteria:\n\n* Individuals under the age of 18 or over the age of 25.\n* Currently pregnant or breastfeeding (female participants).\n* Unwilling or unable to follow protocol requirements","25 Years",{"count":257,"type":20},150,"This study evaluates the amount of nicotine, cannabis, and toxicants linked to the use of nicotine e-cigarette and\u002For cannabis products in the blood and urine of young adult users as well as the cannabis and nicotine use behaviors of consumers.",[26,260],"E-Cig Use","2026-05-04",{"date":263,"type":31},"2026-05-08",{"date":265,"type":31},"2025-04-03",{"date":267,"type":20},"2028-10-01",{"name":64,"class":38},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":287,"locationsCount":87},"100408902","phase-4-nicotine-replacement-therapy-counseling-varenicline-and-bupropion-for-smoking-cessation-the-pisces-i-trial-100408902","NCT04604509","Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial","PISCES I: Precision Implemented Smoking Cessation Evaluation Study","Inclusion Criteria:\n\n* Smoking 5 or more cigarettes, little cigars and\u002For cigarillos per day, on average, within the past 30 days preceding the screening visit and expired carbon monoxide (CO) ≥ 6 ppm and\u002For a urine Nic Check test \\> 0 (or a reading of positive if an alternate nicotine test used)\n* Interested in treatment that might change smoking behavior or help them quit smoking\n* Able to follow verbal and written instructions in English and complete all aspects of the study\n* Provide informed consent and agree to all assessments and study procedures\n* Have an address and telephone number where they may be reached\n* Subjects must report current stable residence in the state of Texas and must not have plans to move out of state in the next 6 months. Stable residence is a domicile in which an individual can operate as if it were his or her own homestead and does not include shelters, halfway houses, treatment centers, or group homes\n* Be the only participant in their household currently receiving treatment on this protocol\n* Agree to be treated via telehealth (live audio-video conference and phone) and to be contacted via text and\u002For email\n* Willing to refrain from the use of other nicotine\u002Ftobacco products for the duration of the study\n\nExclusion Criteria:\n\n* Current enrollment or plans to enroll in another smoking cessation program during the study time frame, including plans to use other smoking cessation medications (i.e., over the counter \\[OTC\\] or prescription medication for smoking cessation) or smoking cessation treatments\n* Serious or unstable medical or psychiatric disorder within the past 3 months, as determined by the study physician\n* Being pregnant, engaging in breast-feeding, or being of childbearing potential and engaging in sexual activity that could lead to pregnancy and is not protected by a medically acceptable, effective method of birth control while enrolled in the study, as determined by self-report. Medically acceptable contraceptives include: (1) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, or (3) an intrauterine device (IUD). Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use\n* Current use of certain medications:\n\n  * Smoking cessation meds (last 7 days; e.g., bupropion, NRT, varenicline). Episodic use of NRT in the last 7 days may be considered if the participant agrees to only use study medication once randomized\n  * Certain medications may be exclusionary and others are precautionary, to be evaluated on a case-by-case basis by study physician (See Exclusionary\u002FPrecautionary Medication List, Appendix 5)\n  * Daily use of opioids for 30 days or more on phone screen or at screening is exclusionary, however as needed (PRN) use is allowed (i.e., 3 out of 7 days per week or less or if more frequent use in less than a month's duration)\n* History of hypersensitivity or allergic reaction to varenicline, NRT, or any component of these formulations as determined by the medical team\n* Self-report of a history or current diagnosis of schizophrenia or bipolar disorder unless cleared by study physician\n* Current substance use disorder (Drug Abuse Screening Test \\[DAST\\] score \\> 3 or use \\>0 in the past year and refuses to refrain from use for the duration of the study; Alcohol Use Disorders Identification Test \\[USAUDIT\\] score \\> 24)\n* Individuals who report depressive symptoms in the moderately severe or severe range on the Patient Health Questionnaire - Mood Module (PHQ-9) (scores of 15 or above); or who report current suicidal ideation on the PHQ-9\n* Individuals who report anxiety symptoms in the severe range on the Generalized Anxiety Disorder Scale (GAD-7) (scores of 15 or above); or meet criteria for panic syndrome on the PHQ Panic module\n* Psychiatric hospitalization within 1 year of screening date\n* Any otherwise not specified medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the principal investigator and\u002For study physician\n* Participant considered by the investigator as unsuitable candidate for full participation in both the treatment and follow-up phases of the study",{"count":277,"type":20},2010,[279],"PHASE4","This phase IV trial investigates how to personalize treatments (such as medications and\u002For counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and\u002For drugs such as varenicline and bupropion may help participants quit smoking or change smoking behavior. This trial may also help doctors individualize smoking cessation treatment for participants who do not quit smoking after the first course of treatment.",[26],"2026-04-28",{"date":261,"type":31},{"date":285,"type":31},"2020-08-04",{"date":84,"type":20},{"name":288,"class":38},"M.D. Anderson Cancer Center",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":87},"100536119","a-comprehensive-evaluation-of-tobacco-flavored-vs-non-tobacco-flavored-e-cigarettes-on-smoking-behavior-100536119","NCT06260683","A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior","A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-Cigarettes on Smoking Behavior","Inclusion Criteria:\n\n* \\>= 21 years old\n* Smoke \\>= 5 cigarettes per day for the past year\n* Willing to use either an EC or NRT\n* Read and speak English\n* Have a smartphone\n\nExclusion Criteria:\n\n* Report currently using smoking cessation medications, NRT, or actively seeking treatment for smoking cessation\n* Current use of an EC \\> 4 days a month\n* Diagnosed medical conditions of lung disease, asthma, cystic fibrosis, heart disease or chronic obstructive pulmonary disease (COPD)\n* Unmanaged (unmedicated and\u002For without counseling) diagnosis of schizophrenia\n* History of cardiac event or distress within the past 3 months\n* Currently pregnant, planning to become pregnant within 6 months, or breastfeeding\n* High blood pressure not controlled by medications\n* Serious angina pectoris or chest pain\n* Stroke within the past three months\n* Known allergy to propylene glycol or vegetable glycerin\n* Serious underlying arrhythmias, irregular heartbeat or abnormal heart rhythm\n* Live in same household as another study participant",{"count":297,"type":20},1500,[76],"This clinical trial compares the use of tobacco flavored electronic cigarettes (ECs) vs. non-tobacco flavored ECs vs. nicotine replacement therapy (patches and lozenges) on smoking behavior in current cigarette smokers. ECs may reduce cigarette craving and withdrawal symptoms, increase motivation and confidence to stop cigarette smoking, and decrease cigarette smoking and dependence. By comparing participants' preferred flavor ECs (PEC) to tobacco flavor ECs (TEC) to NRT, researchers hope to determine the effect of EC flavors on appeal and use and learn how ECs affect smoking behaviors and health.",[26],"2026-04-01",{"date":303,"type":31},"2026-04-06",{"date":305,"type":31},"2024-04-10",{"date":307,"type":20},"2028-04-12",{"name":86,"class":38},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":318,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":87},"100578835","early-phase-1-sensory-tests-of-cigarettes-for-identification-of-flavors-in-current-daily-smoking-adults-100578835","NCT06816459","Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults","Sensory Evaluation of Cigarettes Claiming Removal of Menthol as a Characterizing Flavor","Inclusion Criteria:\n\n* Aged 21-55 years old\n* Current daily smoker of factory-made menthol cigarettes\n* General good health (assessed by self-rated health item)\n* Completion of Brief Smell Identification Test (B-SIT) with no identification of deficits\n\nExclusion Criteria:\n\n* Daily concurrent use of other tobacco products (e.g., e-cigarettes, cigars, smokeless tobacco)\n* Known allergies to mint (peppermint, spearmint), menthol\n* Self-reported olfactory or taste deficits\n* Pregnant or nursing participants, as indicated by self-report\n* History of medications known to interfere with sense of smell\n* Positive diagnosis of coronavirus 2019 (COVID-19) within 10 days of enrollment\n* Current upper respiratory infection or sinus congestion (e.g., cold, flu, seasonal allergies) (by self report)","55 Years",{"count":96,"type":20},[319],"EARLY_PHASE1","This clinical trial tests how well current daily smoking adults can identify flavors of cigarettes. Menthol cigarettes account for 31 percent of cigarettes sold in the United States. Flavors such as menthol play an important role in the start and continued use of tobacco products. Two ways users experience flavor is through smell and taste. Menthol has cooling and numbing properties that can increase perceptions of smoothness and reduce the perceived harshness of smoke. Menthol adds a taste and aroma commonly described as \"minty\". The effect of menthol flavoring on smoking behavior has been studied. Use of menthol cigarettes has been associated with greater nicotine dependence and is associated with both fewer quit attempts and lower odds of quit success. In 2022, the Food and Drug Administration proposed to restrict the use of menthol as a flavor in cigarettes. Menthol has already been banned in Canada, the United Kingdom and the European Union. In late 2022, a restriction on all flavored tobacco products went into effect in California (CA), prompting the tobacco industry to introduce substitute products that did not contain menthol. It is important to find out whether New York (NY) adult smokers who smoke menthol cigarettes can identify and characterize flavors in the same cigarette brand as sold in NY versus CA following the ban of menthol cigarettes in 2022.",[26],"2026-03-31",{"date":303,"type":31},{"date":325,"type":31},"2025-10-14",{"date":327,"type":20},"2027-10-14",{"name":64,"class":38},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":87},"100527284","a-digital-smoking-cessation-intervention-for-helping-american-indians-and-alaska-natives-quit-smoking-indigequit-trial-100527284","NCT06145763","A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial","Digital Smoking Cessation Intervention for Nationally-Recruited American Indians and Alaska Natives: A Full-Scale Randomized Controlled Trial (IndigeQuit)","Inclusion Criteria:\n\n* Self-identify as American Indian or Alaska Native, either alone or in combination with other races\n* Age 18 and older\n* Has smoked daily for the past year\n* Interest in quitting smoking within the next 30 days\n* Willing to be randomly assigned to either app\n* Have daily access to their own Android or iPhone\n* Able to download a smartphone app\n* Be willing and able to read English\n* Not currently or within past 30 days using other smoking cessation behavioral interventions or smoking cessation pharmacotherapies\n* Have never participated in our prior research\n* Have no other household or family member participating\n* Being willing to complete the 3, 6, and 12-month follow-up assessments\n* Providing email, phone number(s), and mailing address\n* Living off United States (US) AI\u002FAN tribal reservations or living on five Northern Plains tribal reservations from whom we would obtain approvals to recruit\n\nExclusion Criteria:\n\n* Currently (i.e., within past 30 days) using other smoking cessation behavioral interventions\n* Has participated in our prior research trials\n* Has used the National Cancer Institute's (NCI's) QuitGuide app\n* Not willing to complete a follow-up survey at 3, 6, and 12 months post-randomization\n* Not providing email, phone number(s), and mailing address",{"count":337,"type":20},776,[76],"This clinical trial compares a new smoking cessation smartphone application (app) (IndigeQuit) to an existing smarphone app (National Cancer Institute \\[NCI\\] QuitGuide) for helping American Indians and Alaska Natives (AI\u002FANs) quit smoking. Compared to other racial\u002Fethnic groups, AIANs have 6 times higher rates of developing smoking-related cancers, including lung cancer. Commercial cigarette smoking accounts for half of all deaths among AIANs nationwide. AIANs' often lack of access to smoking cessation interventions, which may be due to inequities in the healthcare system, lack of health insurance, living in rural areas, systemic racism, and historical trauma. There is also a lack of effective smoking cessation interventions for AIANs. Smartphone apps have the potential to deliver a low-cost smoking cessation intervention with wide reach to AIANs. Apps require no in-person delivery and no provider training, do not require integration into complex hospital systems, can be freely accessed on an app store, and are available at any time and any place. IndigeQuit is a behavioral intervention designed to help adults stop smoking by teaching skills for coping with smoking urges, staying motivated, and preventing relapse. The IndigeQuit app intervention may be more effective than the currently available NCI QuitGuide app at helping AIANs quit smoking.",[26],"2026-02-05",{"date":343,"type":31},"2026-02-09",{"date":345,"type":31},"2025-07-03",{"date":347,"type":20},"2028-11-30",{"name":150,"class":38},{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":21,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":87},"100601495","studying-flavors-and-cooling-agents-in-oral-nicotine-pouches-to-understand-user-preferences-100601495","NCT07111234","Studying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences","Examining the Role of Cooling Agents in Oral Nicotine Pouches","Inclusion Criteria:\n\n* Age 21 years or older\n* Willing to complete study procedures, including abstaining from all tobacco, nicotine, and marijuana for 12 hours before clinic visits\n* Ability to read and speak English\n* Has smoked \\>= 100 cigarettes\n* Smokes \\>= 5 cigarettes\u002Fday for past year\n\nExclusion Criteria:\n\n* Use other tobacco products (including ONPs) more than 10 days per month\n* Unstable or significant psychiatric conditions (past and stable conditions allowed)\n* Pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test before each visit)\n* History of cardiac event or distress within the past 3 months\n* Currently attempting to quit all tobacco use",{"count":96,"type":20},[76],"This clinical trial studies how the flavors and synthetic coolant properties in oral nicotine pouches (ONPs) compare to one another and how these characteristics are perceived by users. ONPs are placed between the gum and lip, and the nicotine is absorbed in the mouth. They have a strong potential for harm reduction if smokers can switch to using them, and they are growing in popularity. One factor that could be contributing to the increase in popularity is the wide range of flavors, including mint or menthol. With recent flavor restriction policies that have gone into effect in certain areas of the United States, ONPs are now including synthetic cooling agents (WS-3) in place of the flavors. They provide a cooling sensation, but do not have a characterizing flavor, like mint or menthol, allowing them to be sold where flavor restriction policies are in place. Learning more about the flavors and cooling properties in ONPs and user preferences may help researchers guide future ONP regulation and understand how these characteristics may be used as a potential harm reduction or quit smoking tool.",[26],"2025-12-18",{"date":362,"type":31},"2025-12-24",{"date":364,"type":31},"2025-09-15",{"date":366,"type":20},"2026-12-31",{"name":86,"class":38},{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":47,"sex":16,"minAge":375,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":21,"phases":379,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":87},"100574048","smoking-cessation-intervention-development-for-homeless-youth-100574048","NCT06754215","Smoking Cessation Intervention Development for Homeless Youth","Development of a Contextually Tailored and Optimized Smoking Cessation Intervention for Homeless Youth","Inclusion Criteria:\n\n* Youth who report having smoked some or every day in the past week.\n* Youth who meet criteria for homelessness defined by the 2002 McKinney-Vento Act including those who lack a fixed, regular, and adequate nighttime residence; live in a welfare hotel, or place without regular sleeping accommodations; or live in a shared residence with other persons due to the loss of one's housing or economic hardship.","14 Years","24 Years",{"count":378,"type":20},298,[76],"This trial develops a contextually tailored and optimized smoking cessation intervention and studies smoking motivations and motivations to quit smoking in homeless youth. Identifying motivations for smoking and motivations to quit smoking may help researchers build a program to help homeless young people quit smoking cigarettes if desired.",[26],"2025-02-05",{"date":384,"type":31},"2025-02-07",{"date":386,"type":31},"2017-09-20",{"date":388,"type":20},"2025-12-31",{"name":86,"class":38}]